CN101573126B - 选择性趋化因子调节 - Google Patents

选择性趋化因子调节 Download PDF

Info

Publication number
CN101573126B
CN101573126B CN2007800413924A CN200780041392A CN101573126B CN 101573126 B CN101573126 B CN 101573126B CN 2007800413924 A CN2007800413924 A CN 2007800413924A CN 200780041392 A CN200780041392 A CN 200780041392A CN 101573126 B CN101573126 B CN 101573126B
Authority
CN
China
Prior art keywords
metal
particles
titanium
use according
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800413924A
Other languages
English (en)
Chinese (zh)
Other versions
CN101573126A (zh
Inventor
L·布鲁斯
S·P·林斯塔多斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PROPHY MED AB
Original Assignee
PROPHY MED AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39184028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101573126(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PROPHY MED AB filed Critical PROPHY MED AB
Publication of CN101573126A publication Critical patent/CN101573126A/zh
Application granted granted Critical
Publication of CN101573126B publication Critical patent/CN101573126B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/38—Removing constituents from donor blood and storing or returning remainder to body, e.g. for transfusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/06—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group B01J20/04
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
CN2007800413924A 2006-09-12 2007-09-11 选择性趋化因子调节 Expired - Fee Related CN101573126B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84376006P 2006-09-12 2006-09-12
US60/843,760 2006-09-12
PCT/SE2007/000785 WO2008033069A1 (en) 2006-09-12 2007-09-11 Selective chemokine modulation

Publications (2)

Publication Number Publication Date
CN101573126A CN101573126A (zh) 2009-11-04
CN101573126B true CN101573126B (zh) 2012-04-25

Family

ID=39184028

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800413924A Expired - Fee Related CN101573126B (zh) 2006-09-12 2007-09-11 选择性趋化因子调节

Country Status (17)

Country Link
US (3) US8784845B2 (cg-RX-API-DMAC10.html)
EP (1) EP2068895B1 (cg-RX-API-DMAC10.html)
JP (1) JP5290179B2 (cg-RX-API-DMAC10.html)
KR (1) KR101419963B1 (cg-RX-API-DMAC10.html)
CN (1) CN101573126B (cg-RX-API-DMAC10.html)
AU (1) AU2007295138B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0716728A2 (cg-RX-API-DMAC10.html)
CA (1) CA2663259C (cg-RX-API-DMAC10.html)
ES (1) ES2401031T3 (cg-RX-API-DMAC10.html)
IL (1) IL197562A (cg-RX-API-DMAC10.html)
MX (1) MX2009002699A (cg-RX-API-DMAC10.html)
MY (1) MY148756A (cg-RX-API-DMAC10.html)
NO (1) NO341876B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ576190A (cg-RX-API-DMAC10.html)
RU (1) RU2446809C2 (cg-RX-API-DMAC10.html)
SG (1) SG174094A1 (cg-RX-API-DMAC10.html)
WO (1) WO2008033069A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE531319C2 (sv) 2007-02-22 2009-02-24 Tigran Technologies Ab Publ Porös implantatgranul
US9957311B2 (en) 2013-12-20 2018-05-01 Tikomed Ab Surface-binding peptide
CN104020297B (zh) * 2014-06-10 2016-12-07 上海交通大学医学院 用于结核分枝杆菌感染检测及临床治疗效果监测的试剂盒及其用途
JP6631499B2 (ja) * 2016-12-27 2020-01-15 トヨタ自動車株式会社 ハイブリッド車両の制御装置
CA3183415A1 (en) 2020-05-11 2021-11-18 Minnetronix Neuro, Inc. Filtering cassettes and filtering systems

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012180A2 (en) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce
US20030055106A1 (en) * 1999-08-12 2003-03-20 Robert Faure Therapeutic uses of peroxometallic compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2252729B (en) 1991-02-13 1994-11-09 Bharat Sridhar Pancham Vitamin and/or mineral containing pharmaceutical compositions
EP0686848A1 (en) 1994-05-09 1995-12-13 Shiseido Company Limited Liquid chromatograph having a micro and semi-micro column
DE19938668B4 (de) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6527951B1 (en) * 2000-11-16 2003-03-04 Waters Investments Limited Chromatographic column
US20050119105A1 (en) * 2002-01-18 2005-06-02 Schott Ag Glass-ceramic composite containing nanoparticles
DE10201747C1 (de) 2002-01-18 2003-08-14 Schott Glas Glas-Keramik-Komposit, Verfahren zu seiner Herstellung und Verwendungen
US20100018928A1 (en) * 2004-11-16 2010-01-28 Waters Investments Limited Device for performing separations and methods of making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012180A2 (en) * 1999-08-12 2001-02-22 UNIVERSITé LAVAL Peroxovanadium compounds as protein tyrosine phosphatase (ptp) inhibitors: their inhibitory effects on angiogenesis, restenosis and the production of endothelins, and their stimulating effects on the immune responce
US20030055106A1 (en) * 1999-08-12 2003-03-20 Robert Faure Therapeutic uses of peroxometallic compounds

Also Published As

Publication number Publication date
EP2068895A4 (en) 2009-12-23
EP2068895A1 (en) 2009-06-17
SG174094A1 (en) 2011-09-29
US9649426B2 (en) 2017-05-16
KR101419963B1 (ko) 2014-07-30
RU2009113579A (ru) 2010-10-20
RU2446809C2 (ru) 2012-04-10
CN101573126A (zh) 2009-11-04
US8784845B2 (en) 2014-07-22
WO2008033069A1 (en) 2008-03-20
US20100203089A1 (en) 2010-08-12
NZ576190A (en) 2011-06-30
NO20091420L (no) 2009-06-11
JP2010503666A (ja) 2010-02-04
AU2007295138A1 (en) 2008-03-20
IL197562A (en) 2013-12-31
BRPI0716728A2 (pt) 2017-06-13
US20140302149A1 (en) 2014-10-09
NO341876B1 (no) 2018-02-12
WO2008033069A8 (en) 2009-07-23
CA2663259A1 (en) 2008-03-20
US9656015B2 (en) 2017-05-23
KR20090069293A (ko) 2009-06-30
US20140299548A1 (en) 2014-10-09
MY148756A (en) 2013-05-31
ES2401031T3 (es) 2013-04-16
AU2007295138B2 (en) 2012-10-04
IL197562A0 (en) 2009-12-24
JP5290179B2 (ja) 2013-09-18
CA2663259C (en) 2017-01-03
EP2068895B1 (en) 2012-12-12
MX2009002699A (es) 2009-06-11

Similar Documents

Publication Publication Date Title
US9656015B2 (en) Selective chemokine modulation
EP2552459B1 (en) Method of treating inflammation
JP2009525297A5 (cg-RX-API-DMAC10.html)
Szczeklik et al. Cutting edge issues in the Churg–Strauss syndrome
JP5234445B2 (ja) 薬剤
EP2970381A2 (en) Methods for making cytokine compositions from tissues using non-centrifugal methods
CN114099481B (zh) 雾化吸入型糖皮质激素纳米药物及其制备方法和应用
WO2022150839A1 (en) Immune modulation by mesenchymal stem cells
CN114191436A (zh) 仿生巨噬细胞膜纳米载药颗粒的合成方法及其在新冠病毒肺炎中的应用
CN116672338A (zh) 蟛蜞菊内酯在制备治疗系统性红斑狼疮药物中的应用
Eb et al. Oxidative stress indices and inflammatory responses in female wistar rats administered acetaminophen, ampicillin/cloxacillin and co-trimoxazole
Alrashedi et al. Detection of Association Between Some of Nanoparticles (Zn, Ag) and Rheumatoid Arthritis in Rats
Li et al. Expression of Nod-Like Receptor Protein 3 (NLRP3) in Peripheral Blood Mononuclear Cells of Patients with Sepsis
US20230364152A1 (en) Compositions and methods of use for infusible extracellular matrix
Matsui Leukocyte removal therapy before surgery in ulcerative colitis
Yoo et al. Nanodiamond as a Cytokine Sponge in Infectious Diseases. Front. Bioeng. Biotechnol. 10: 862495. doi: 10.3389/fbioe. 2022.862495
CN112043689A (zh) 一种用于抑制脂多糖诱导巨噬细胞炎症的药物组合物及其应用
Lu et al. Changes of plasma cytokines in patients with severe hepatitis treated with a probiotic preparation
CN110812362A (zh) 腺嘌呤在制备治疗β地中海贫血的药物中的应用
Ahmad et al. Renal and hepatic outcomes after Remdesivir therapy in COVID-19 positive patients with renal dysfunction at baseline or after starting therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120425

Termination date: 20200911